- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$146.18 MnMarket Estimate, 2026
$166.84 MnMarket Forecast, 2034
$480 MnCAGR, 2026–2034
14.13%Asia Pacific Preimplantation Genetic Testing Market Size, Growth, Trends & Forecast (2026–2034)
The Asia Pacific preimplantation genetic testing market size was valued at USD 146.18 million in 2025, stands at USD 166.84 million in 2026, and is projected to reach USD 480.00 million by 2034, registering a compound annual growth rate (CAGR) of 14.13% during the forecast period from 2026 to 2034. The market expansion is heavily driven by rising infertility rates, expanding IVF clinic infrastructure, surging parental awareness regarding genetic disorders, and advanced technological integration.
Key Executive Metrics (At-a-Glance)
- 2025 Base Valuation: USD 146.18 Million
- 2026 Current Valuation: USD 166.84 Million
- 2034 Forecast Valuation: USD 480.00 Million
- Compound Annual Growth Rate (CAGR): 14.13% (2026–2034)
- Dominant Procedure Type Segment: Genetic Screening (PGS/PGT-A) (holding the largest market share due to routine aneuploidy testing in IVF cycles)
- Fastest-Growing Procedure Type Segment: Genetic Diagnosis (PGT-M/SR) (registering high adoption for targeted monogenic and structural disorder identification)
- Dominant Technology Segment: Next-Generation Sequencing (NGS) (capturing the maximum share due to high-resolution genomic data and precision)
- Fastest-Growing Technology Segment: Next-Generation Sequencing (NGS) / Advanced Molecular Arrays
- Dominant Application Segment: Structural Chromosomal Abnormalities & Aneuploidy Screening (leading clinical volume)
- Fastest-Growing Application Segment: Single Gene Disorders (showing accelerated demand among high-risk couples)
- Dominant End User Segment: Fertility Clinics (commanding the primary share as principal providers of assisted reproductive treatments)
- Fastest-Growing End User Segment: Specialized Diagnostic Laboratories (scaling rapidly via outsourced genetic panels)
- Dominant Country Market: China & India (leading regional contributions backed by massive patient volumes and expanding IVF infrastructure)
Core Market Drivers
- Rising Infertility Rates: Delayed childbearing patterns and lifestyle factors increasing reliance on Assisted Reproductive Technology (ART) and embryo screening.
- Technological Advancements: Continuous improvement in genetic analysis tools like NGS, enabling cost-effective, simultaneous multi-condition embryo profiling.
Primary Market Restraints & Challenges
- High Procedural Costs: Substantial out-of-pocket expenses for PGT services limiting accessibility in developing sub-regions.
- Regulatory Complexity & Infrastructure Gaps: Restrictive policy frameworks and uneven healthcare resources across emerging rural economies.
Asia Pacific Preimplantation Genetic Testing Market Segmentation Breakdown
| Segment Category | Largest (Dominant) Sub-Segment | Fastest-Growing Sub-Segment |
|---|---|---|
| By Procedure Type | Genetic Screening (PGS) | Genetic Diagnosis (PGT-M/SR) |
| By Technology | Next-Generation Sequencing (NGS) | Next-Generation Sequencing (NGS) |
| By Products & Services | Reagents And Consumables | Software And Services |
| By Application | Structural Chromosomal Abnormalities / Aneuploidy | Single Gene Disorders |
| By End User | Fertility Clinics | Diagnostic Laboratories |
| By Country | China & Japan | India |
Major Industry Players Profiled
Key genetic testing leaders and diagnostics providers shaping the market include Illumina, Inc., Yikon Genomics, CooperSurgical, Oxford Gene Technology, Inc., Thermo Fisher Scientific, Inc., Rubicon Genomics, Inc., Agilent Technologies, Inc., Natera, Inc., Abbott Laboratories, PerkinElmer, Inc., and SciGene Corporation.
Download Free Sample Report
Asia Pacific Preimplantation Genetic Testing Market Size
The Asia Pacific preimplantation genetic testing market was valued at USD 146.18 million in 2025, is estimated to reach USD 166.84 million in 2026, and is projected to reach USD 480 million by 2034, growing at a CAGR of 14.13% from 2026 to 2034.
MARKET DRIVERS
Rising Infertility and Genetic Disorders Fuel Growth of Preimplantation Genetic Testing Market
The growth of this market is mainly driven by the increasing rate of infertility in the world, the increase in the number of fertility clinics in the world, the public-private investments in the field of preimplantation genetic tests, the technological advances in the field of genetic analysis and the high risk of chromosomal abnormalities in the fetus with increasing maternal age.
The main factor attributed to the growth of the market is increased parental awareness of diagnostic advancements with high volume of neonatal deaths due to complications in childbirth. In recent years, the increasing prevalence of congenital genetic diseases and common pediatric respiratory disorders has been observed. These abnormalities occur almost exclusively in couples with inherited disorders, which have been found to occur mainly in industrialized countries. Therefore, the increased demand for early diagnosis and increased government efforts to control the burden of healthcare are likely to boost the market for preimplantation genetic testing.
Early diagnosis of chromosomal disorders helps reduce the number of people with congenital diseases. These factors are expected to drive demand for preimplantation genetic testing (PGT) market. It is estimated that the increasing number of incidences of various gene related disorders will support the market growth over the next coming years.
MARKET RESTRAINTS
High Costs, Regulations, and Poor Infrastructure Restrain PGT Market in Asia Pacific
The high procedural cost associated with preimplantation genetic testing and unfavorable government regulations are the major factors limiting the growth of this market. Recently, PGT technology is integrated with Assisted Reproductive Technology (ART) procedures to deliver the best results to patients around the world. Technological advances and the relatively high accuracy of the results encourage a greater preference for this diagnostic modality. In addition, the detection of monogenic disorders is more beneficial than conventional prenatal diagnostic tests on embryos, which is driving the market for PGT. The poor healthcare infrastructure is expected to be the main challenge in developing countries of Asia Pacific region.
REPORT COVERAGE
| REPORT METRIC | DETAILS |
| Market Size Available | 2026 to 2034 |
| Base Year | 2025 |
| Forecast Period | 2026 to 2034 |
| Segments Covered | By Procedure Type, Technology, Products & Services, Application, End User, and Country. |
| Various Analyses Covered | Global, Regional and Country-Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
| Countries Covered | India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore, and Rest of APAC |
| Market Leaders Profiled | Illumina, Inc., Yikon Genomics, CooperSurgical, Oxford Gene Technology, Inc., Thermo Fisher Scientific, Inc., Rubicon Genomics, Inc., Agilent Technologies, Inc., Natera, Inc., Abbott Laboratories, PerkinElmer, Inc., and SciGene Corporation. |
REGIONAL ANALYSIS
Known for providing excellent medical services at very economical rates compared to developed regions, the healthcare industry in Asia has invited patients from all over the world. With continuous advancements in healthcare infrastructure, an increasing number of healthcare experts, and constant improvement in diagnostic facilities, Asia is expected to be a major hub for the PGT market in the future. Many global healthcare and diagnostic providers are expanding their businesses in Asia and the number of fertility clinics, hospitals and diagnostic centers is steadily increasing in the region.
Fertility clinics held a significant share of the overall Asian PGD market in 2018, and are expected to post a CAGR of 5.5% during the period 2026-2034. The booming tourism industry in the region is leading to the establishment of an increasing number of IVF centers and health facilities, such as hospitals and diagnostic centers in the region.
In the coming years, the Asian PGT market is expected to experience the strongest growth in southern countries such as India and China. The high and increasing rate of infertility in South Asian countries, the increase in disposable income and the high percentage of women in the workforce will enable the region to present more attractive growth opportunities for the Asian IPR market.
KEY MARKET PLAYERS
Top companies leading in the Asia Pacific Preimplantation Genetic Testing Market profiled in the report are Illumina, Inc., Yikon Genomics, CooperSurgical, Oxford Gene Technology, Inc., Thermo Fisher Scientific, Inc., Rubicon Genomics, Inc., Agilent Technologies, Inc., Natera, Inc., Abbott Laboratories, PerkinElmer, Inc., and SciGene Corporation.
MARKET SEGMENTATION
This research report on the Asia Pacific preimplantation genetic testing market has been segmented and sub-segmented into the following categories:
By Procedure Type
- Genetic Diagnosis
- Genetic Screening
By Technology
- NGS
- PCR
- FISH
- CGH
- SNP
By Products & Services
- Reagents And Consumables
- Instruments
- Software And Services
By Application
- Structural Chromosomal Abnormalities
- Single Gene Disorders
- X-Linked Disorders
- HLA Typing
- Gender Identification
By End User
- Fertility Clinics
- Hospitals
- Research Laboratories
By Country
- India
- China
- Japan
- South Korea
- Australia
- New Zealand
- Thailand
- Malaysia
- Vietnam
- Philippines
- Indonesia
- Singapore
- Rest of Asia Pacific